Pharmacodynamic Biomarkers for Biosimilar Approval

The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public workshop entitled "[Pharmacodynamic Biomarkers for Biosimilar Approval]." his public workshop is to discuss the initiatives the FDA has undertaken over the past few years to identify pharmacodynamic (PD)...

The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public...

Read More